Despite that dual-targeted therapy with trastuzumab and pertuzumab remains the standard neoadjuvant regimen for HER2-positive breast cancer, the use of pyrotinib can enrich clinical treatment options. This evidence concerns the gene ERBB2 and breast cancer.